$ACMR

Wang David H sold $560K of ACMR

Wang David H (See Remarks) sold 6,295 shares of ACM Research, Inc. (ACMR) at $88.98 ($0.56M total) on 2026-06-03 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Wang David H
Published Jun 5, 2026, 8:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 5, 2026, 8:36 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$ACMR
Neutral
medium confidence
Mentioned
$ACMR
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ACMRNeutralLow
01

Why it matters

A disclosed open-market sale by an insider under a pre-arranged 10b5-1 plan is generally treated as low-signal for fundamentals; it can modestly influence sentiment if traders interpret it as risk reduction.

02

Market read

Traders may note the insider sale for sentiment monitoring, but the 10b5-1 structure makes it unlikely to drive a major repricing by itself.

03

What to watch

The article provides no context on total insider ownership changes beyond the post-transaction holdings, nor any concurrent operational/financial developments.

Relevance 6/10Novelty 3/10Timing: Filed after-hours (SEC EDGAR timestamp 2026-06-05 16:30 ET) for a 2026-06-03 sale.

Background

The article is an SEC Form 4 insider transaction disclosure for ACM Research, Inc. (ACMR).

Company-level read

Ticker impact

$ACMRNeutralMedium confidence
Context

ACMR insider (officer/director/10% owner) sold 6,295 shares in an open-market transaction under a pre-arranged 10b5-1 plan.

Expected impact

Low likelihood of a sustained price move solely from this Form 4; any reaction is likely muted due to 10b5-1 pre-arrangement.

Evidence & confidence

Form 4 insider sales are typically informational for sentiment, but the presence of a pre-arranged 10b5-1 plan reduces the signal of new negative information.

Market effects

No clear sector read-through; this is company-specific insider transaction disclosure.

None indicated.

None indicated.

Counterpoint

Even with 10b5-1, repeated insider selling can still coincide with periods of valuation risk or liquidity needs; traders may watch for clustering across filings.

Key entities

  • ACM Research, Inc.

    Subject of the Form 4 insider sale disclosure.

  • Wang David H

    Officer/director/10% owner who sold shares under a 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$ACMRMed

AI Sovereignty Becomes a New National Security Battleground: Morgan Stanley Names SpaceX and 4 Other Beneficiary Stocks, with Upside Potential Topping 100% — BigGo Finance

Morgan Stanley identifies SpaceX, ACM Research, Amkor Technology, Alibaba, and KLA as key beneficiaries of the AI sovereignty trend. The bank assigns price targets with upside potential ranging from 21% to 105%, highlighting the strategic importance of AI infrastructure for national security and economic competitiveness.

$ACMRMed

ACM Research (NASDAQ: ACMR) unit’s orders surge past 100% with 42–48% margin outlook

ACM Research (Shanghai) reported a 105% year-over-year increase in new orders for the first half of 2026, with growth across electroplating, cleaning, and advanced packaging equipment. The company expects gross margins to remain between 42% and 48%. Significant orders include panel-level electroplating systems for delivery in 2026 and 2027. ACM Shanghai also highlighted rapid growth in mature-node semiconductor manufacturing and AI-related equipment demand.

$ACMRMedAI 9/10

ACM Research (ACMR) Q2 2026 Earnings Call Transcript

ACM Research (ACMR) reported Q2 2026 revenue of $292.9M, up 36% year over year, with non-GAAP diluted EPS of $0.61. Non-GAAP gross margin was 46.0%. The company raised 2026 revenue guidance to $1.125B-$1.175B and said first-half orders rose 105%. Net cash was $1.0B.